Abstract:Background: A recurring single amino acid somatic mutation associated with nearly 1/3 of human diffuse large B cell lymphomas (DLBCLs), over 90% of Waldenström macroglobulinemia (WM) and 54% of immunoglobulin M monoclonal gammopathy, has been identified within the myeloid differentiation factor 88 (MyD88). This gain of function single amino acid mutation correlates with tumor cell proliferation and survival involving spontaneous and sustained activation of MyD88-dependent NF-κB and Janus Kinase (JAK) signaling pathways. MyD88 acts as a central signaling adapter for mediating innate and cytokine driven inflammation for the Interleukin-1 (IL-1R) and Toll-like receptors (TLRs). In normal healthy cells, MyD88 is thought to be held in an auto-inhibitory state with its own death and TIR domains fused together in negative self-regulation until activated by appropriate receptor mediated ligand engagement, involving Toll-like or Interleukin-1 ligands. We propose the oncogenic mutation, MyD88L265P located within the TIR domain of MyD88 results in discrete structural changes which releases binding and auto-inhibition of MyD88 death domains resulting in MyDDosome assembly, spontaneous recruitment of IL-1 receptor associated kinases (IRAKs) and sustained signaling. Observation: Recently, CADD derived small molecule compounds which inhibit MyD88 dimer formation have been identified and functionally characterized to protect against Staphylococcal enterotoxin B (SEB) induced death in animal models. Hypothesis: Based on their ability to target MyD88 in protection against Staphylococcal enterotoxin B induced death we hypothesize that CADD derived MyD88 small molecule inhibitors may also be useful therapeutic agents in treating DLBCLs bearing the oncogenic mutation MYD88L265P by inhibiting MyDDosome formation and subsequent recruitment of IL-1 receptor associated kinases. Approach: Using in vitro and in vivo studies we are evaluating MyD88 specific small molecule inhibitors for the ability to inhibit tumor cell proliferation, MyDDsome assembly, IRAK recruitment and signaling in human patient cancer cells OCI Ly3 and OCI Ly19 bearing the oncogenic mutation MYD88L265P. Results: We show (1) MyD88 small molecule inhibitors are able to inhibit cell proliferation of activated human B cell lymphoma cells bearing the MyD88L265P mutation using a MTS cell proliferation assay, (2) Purified recombinant MyD88 and small molecule inhibitors exhibit unique binding chromatograms in comparison to vehicle controls using a thermal shift assay and (3) MyD88 SMIs inhibit LPS activated TLR4-blue cell NF-kB signaling in comparison to the TLR4 specific inhibitor TAK242. We are continuing to biochemically characterize MyD88 small molecule inhibitors as well as test additional human cancer cells bearing oncogenic MyD88 mutations. Conclusions: CADD derived MyD88 specific SMIs previously shown to be effective in protection again microbial infection and death may also be useful in targeting B cell lymphoma cells bearing the MyD88L265P mutation. Future studies defining the molecular mechanism of this MyD88L265P specific mutation associated with nearly one third of human patient tumor isolates will rationally inform and propel development of novel therapeutics to counteract both inflammation as well as tumor cell formation.

Targeting of MyD88 Homodimerization by Novel Synthetic Inhibitor TJ-M2010-5 in Preventing Colitis-Associated Colorectal Cancer.

Blockade of Myd88 Signaling by Novel MyD88 Inhibitor Prevents Colitis-associated Colorectal Cancer From Development by Impairing Myeloid-Derived Suppressor Cells

Short-term Use of MyD88 Inhibitor TJ-M2010-5 Prevents D-Galactosamine/lipopolysaccharide-induced Acute Liver Injury in Mice.

Implication of Myeloid Differentiation Factor 88 Inhibitor TJ-M2010-5 for Therapeutic Intervention of Hepatocellular Carcinoma.

MyD88 in Myofibroblasts Enhances Colitis-Associated Tumorigenesis Via Promoting Macrophage M2 Polarization

Blocking MyD88 signaling with MyD88 inhibitor prevents colitis-associated colorectal cancer development by maintaining colonic microbiota homeostasis

Abstract 4966: MyD88 in Myofibroblasts Enhances Colitis-Associated Tumorigenesis Via Promoting Macrophage M2 Polarization in Mice

Modulating the Conformation of the TIR Domain by a Neoteric MyD88 Inhibitor Leads to the Separation of GVHD from GVT.

Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.

Inhibition of MyD88 by a Novel Inhibitor Reverses Two-Thirds of the Infarct Area in Myocardial Ischemia and Reperfusion Injury

Beyond Knockout: A Novel Homodimerization-Targeting MyD88 Inhibitor Prevents and Cures Type 1 Diabetes in NOD Mice

Suppression of Transmembrane Tumor Necrosis Factor Alpha Processing by a Specific Antibody Protects Against Colitis-Associated Cancer

Prevention of Experimental Colitis in SCID Mice Reconstituted with CD45RBhigh CD4+ T Cells by Blocking the CD40-CD154 Interactions1

Synthetic lethality between MyD88 loss and mutations in Wnt/β-catenin pathway in intestinal tumor epithelial cells

PC-11 Select Targeting of Diffuse Large B-cell Lymphomas Using MyD88 Small Molecule Inhibitors

Pharmacological Inhibition Of Myd88 Homodimerization Counteracts Renal Ischemia Reperfusion-Induced Progressive Renal Injury In Vivo And In Vitro

Tocotrienol suppresses colitis-associated cancer progression through TLR4 signaling in a mouse model of colorectal cancer

Toll-like receptor 3 signaling attenuated colitis-associated cancer development in mice

Tropomyosin 2 Regulates Tumor Cell Proliferation, Immune Suppression, and Activation of the JNK Signaling Pathway in Colitis-Associated Cancer (CAC)

The MyD88 inhibitor TJ-M2010-2 suppresses proliferation, migration and invasion of breast cancer cells by regulating MyD88/GSK-3β and MyD88/NF-κB signalling pathways

Dual TNF-α/IL-12p40 Interference as a Strategy to Protect Against Colitis Based on miR-16 Precursors With Macrophage Targeting Vectors.